Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Fulgent Genetics, |
RCV002642488 | SCV005661946 | likely pathogenic | 3-methylcrotonyl-CoA carboxylase 1 deficiency | 2024-05-14 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV002642488 | SCV002970235 | pathogenic | 3-methylcrotonyl-CoA carboxylase 1 deficiency | 2022-01-27 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant is also known as c.1731+1del. This variant has not been reported in the literature in individuals affected with MCCC1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ile578Leufs*21) in the MCCC1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MCCC1 are known to be pathogenic (PMID: 11181649, 15359379, 22642865). For these reasons, this variant has been classified as Pathogenic. |